Question · asked by 1 review
First‐line angiotensin converting enzyme inhibitor vs placebo: Cardiovascular events
- Population
- adults with primary hypertension
- Intervention
- First‐line angiotensin converting enzyme inhibitor
- Comparison
- placebo
- Outcome
- Cardiovascular events
First‐line angiotensin converting enzyme inhibitor probably leads to lower total cardiovascular events compared with placebo (moderate certainty).
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
First‐line angiotensin converting enzyme inhibitor vs placebo Total cardiovascular events · adult patients with primary hypertension First‐line angiotensin converting enzyme inhibitor probably leads to lower total cardiovascular events compared with placebo (moderate certainty). First‐line drugs for hypertension (2018) · Cochrane Headline outcomes only | RR 0.76 [0.67, 0.85] | 2 studies · 5145 participants | Moderate |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| First‐line drugs for hypertension 2018 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.